Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-10 |
2024-03 |
0 |
0.23 |
N/A |
N/A |
2024-03-28 |
2023-12 |
0 |
-0.57 |
N/A |
N/A |
2023-11-09 |
2023-09 |
-1.05 |
-1.03 |
0.02 |
1.90% |
2023-08-10 |
2023-06 |
-1.23 |
-1.04 |
0.19 |
15.45% |
2023-05-12 |
2023-03 |
0 |
-1.22 |
N/A |
N/A |
2023-03-30 |
2022-12 |
-1.44 |
-1.14 |
0.3 |
20.83% |
Date |
Firm |
Action |
From |
To |
2023-08-14 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-05-14 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-02-06 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2022-03-29 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2017-03-21 |
CLARKE ROBERT W PH.D. |
Chief Executive Officer |
4.53K |
Conversion of Exercise of derivative security |
2014-05-08 |
FRENCH GREGORY M |
Director |
58.00K |
Stock Award(Grant) |
2018-04-02 |
GILLIS STEVEN |
Director |
0.00 |
Purchase |
2017-03-21 |
HAVA DAVID L |
Officer |
2.26K |
Conversion of Exercise of derivative security |
2018-04-02 |
IWICKI MARK T. |
Director |
307.00K |
Purchase |
2015-06-15 |
MAKI DAVID |
Director |
0.00 |
Purchase |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Sabby Management, LLC |
184.07K |
493.32K |
5.04% |
2023-06-29 |
Renaissance Technologies, LLC |
109.01K |
292.15K |
2.98% |
2023-06-29 |
Blackrock Inc. |
54.90K |
147.13K |
1.50% |
2023-06-29 |
Geode Capital Management, LLC |
24.62K |
65.99K |
0.67% |
2023-06-29 |
Vanguard Group Inc |
21.39K |
57.33K |
0.59% |
2023-06-29 |
State Street Corporation |
13.95K |
37.37K |
0.38% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Extended Market Index Fund |
21.39K |
57.33K |
0.59% |
2023-05-30 |
Fidelity Extended Market Index Fund |
13.78K |
37.60K |
0.38% |
2023-06-29 |
Bridgeway Funds Inc-Ultra Small Company Fund |
9.70K |
26.00K |
0.27% |
2023-05-30 |
Fidelity Total Market Index Fund |
4.45K |
12.16K |
0.12% |
2023-05-30 |
Fidelity Series Total Market Index Fund |
4.16K |
11.34K |
0.11% |
2023-05-30 |
Fidelity NASDAQ Composite Index Fund |
2.22K |
6.06K |
0.06% |
Split |
Date |
1 : 20 |
2022-03-01 |
1 : 10 |
2019-02-06 |
4 : 10 |
2015-06-16 |